Table 1.
Clinical trials evaluating venetoclax-based combination regimens
| Drug Regimen | Treatment Category | Mutation (if required for eligibility) | Clinicaltrials.gov identifier | Target Number of patient enrollment++ | Phase | Year of study initiation |
| Azacitidine + Venetoclax | Frontline | NCT03466294 | 42 | II | 2018 | |
| Venetoclax + Decitabine | Both+ | NCT03404193 | 400 | II | 2018 | |
| ASTX727 (Decitabine and Cedazuridine) + Venetoclax |
Both+ | NCT04657081 | 124 | I/II | 2021 | |
| ASTX727 (Decitabine and Cedazuridine) + Venetoclax | Both+ | NCT04746235 | 40 | II | 2021 | |
| Venetoclax + Cladribine + LDAC induction followed by Cladribine+ LDAC + Azacitidine | Frontline | NCT03586609 | 85 | II | 2018 | |
| LDAC + Venetoclax^^ | Frontline | NCT02287233 | 94 | I/II | 2014 | |
| LDAC + Venetoclax vs LDAC + placebo | Frontline | NCT03069352 | 211 | III | 2017 | |
| CPX-351 (Liposome-encapsulated Daunorubicin-Cytarabine) + Venetoclax | Both+ | In RR subset, (+) RAS pathway activating mutation: KIT, HRAS/NRAS/KRAS, BRAF, CBL or PTPN11 or loss of function mutation of NF1 | NCT03629171 | 52 | II | 2018 |
| Ivosidenib (IDH1 inhibitor) + Venetoclax +/- Azacitidine | Both+ | IDH1+ | NCT03471260 | 30 | I/II | 2018 |
| Enasidenib (IDH2 inhibitor) + Venetoclax | Both+ | IDH2 (+) | NCT04092179 | 48 | I/II | 2020 |
| Gilteritinib (FLT3 inhibitor) + Venetoclax^^ | Salvage | NCT03625505 | 61 | I | 2018 | |
| Gilteritinib (FLT3 inhibitor) + Azacitidine + Venetoclax | Salvage | FLT3 | NCT04140487 | 42 | I/II | 2019 |
| Gilteritinib (FIT3 inhibitor) + ASTX727 (Decitabine and Cedazuridine) + Venetoclax | Salvage (phase I), Both (phase II)+ | FLT3 | NCT05010122 | 42 | I/II | 2021 |
| Quizartinib (FLT3 inhibitor) + Venetoclax | Salvage | FLT3 | NCT03735875 | 32 | I/II | 2019 |
| Quizartinib (FLT3 inhibitor) + Decitabine + Venetoclax | Both+ | FLT3 | NCT03661307 | 52 | I/II | 2018 |
| S64315 (MCL-1 inhibitor) + Venetoclax | Salvage | NCT03672695 | 40 | I | 2018 | |
| AZD5991 (MCL-1 inhibitor) + Venetoclax** | Salvage | NCT03218683 | 144 | I/II | 2017 | |
| Pevonedistat (NAE inhibitor) +/- Venetoclax + Azacitidine | Frontline | NCT03862157 | 40 | I/II | 2019 | |
| Cobimetinib (MEK inhibitor) + Venetoclax; Idasanutlin (MDM2 inhibitor) + Venetoclax^^ |
Salvage | NCT02670044 | 88 | I | 2016 | |
| Trametinib (MEK inhibitor) + Azacitidine + Venetoclax | Both+ | (+) RAS pathway activating mutation in R/R subset | NCT04487106 | 40 | II | 2020 |
| Dinaciclib (CDK inhibitor) + Venetoclax | Salvage | NCT03484520 | 48 | I | 2018 | |
| Alvocidib (CDK inhibitor) + Venetoclax^^ | Salvage | NCT03441555 | 36 | I | 2018 | |
| CYC065 (CDK inhibitor) + Venetoclax | Salvage | NCT04017546 | 25 | I | 2019 | |
| APR-246 + Venetoclax +/- Azacitidine | Frontline | TP53 + | NCT04214860 | 51 | I | 2019 |
| Magrolimab + Venetoclax + Azacitidine or MEC or CC-486 (oral Azacitidine) | Both+ | NCT04778410 | 164 | II | 2021 | |
| Magrolimab + Azacitidine + Venetoclax | Frontline (phase I), Salvage (phase II) | NCT04435691 | 98 | I/II | 2021 | |
| ALX148 (Evorpacept) + Venetoclax + Azacitidine | Both+ | NCT04755244 | 97 | I/II | 2021 | |
| TTI-622 (SIRPα-IgG4 Fc) + AZA +/-VEN | Frontline | TP53 +/- | NCT03530683 | 150 | I | 2018 |
| Ph I/IIb DS-1594 (Menin inhibitor) +/- Azacitidine + Venetoclax or miniHCVD | Salvage | Presence of MLL rearrangement, NPM1 (+) | NCT03735875 | 32 | I/II | 2019 |
MEC Mitoxantrone, Etoposide, and Cytarabine. vs. ^^Completed. **Suspended. +Both frontline and salvage therapy. ++Actual number of patients enrolled for completed studies.